Astral Systems

Bristol-based Astral Systems, a deep-tech company specializing in nuclear fusion technology for medical applications, has successfully raised £23 million in the first close of its Series A investment round.

Summary of transaction details:

• Value: £23 million
• Sector: Healthcare & Biotech
• Advisor: Not explicitly mentioned
• Key Entities: Astral Systems (Target), Mercia Ventures (Lead Investor), Tees River, Daphni, Blast Club, Speedinvest, Playfair Capital (Co-investors)
• Location: Bristol, UK (Target Company)

Note: This funding will accelerate Astral Systems' development of medical isotopes crucial for cancer diagnosis and treatment, expand its modular reactor production, and advance its fusion research, addressing critical shortages in the healthcare sector.